CIK 0001061983
CYTK CYTOKINETICS INC
Insider trading from SEC Form 4. Last filing Dec 16, 2024.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Signals
Open-market buys and sells at CYTOKINETICS INC, scored.
| Score | Side | Insider | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 1Weak | sell 410b5-1 | WIERENGA WENDALL director | $36k | 742 | -3% | - | |
| 4Weak | sell 410b5-1 | HENDERSON JOHN T director | $90k | 1,780 | -4% | - | |
| 10Weak | sell 410b5-1 | Malik Fady Ibraham EVP Research & Development | $370k | 7,300 | -6% | - | |
| 18Weak | sell 410b5-1 | Blum Robert I President & CEO | $254k | 5,000 | -1% | - | |
| 1Weak | sell 310b5-1 | WIERENGA WENDALL director | $37k | 742 | -3% | - | |
| 10Weak | sell 310b5-1 | Malik Fady Ibraham EVP Research & Development | $366k | 7,300 | -6% | - | |
| 18Weak | sell 310b5-1 | Blum Robert I President & CEO | $253k | 5,000 | -1% | - | |
| 10Weak | sell 310b5-1 | Malik Fady Ibraham EVP Research & Development | $371k | 6,342 | -5% | - | |
| 18Weak | sell 310b5-1 | Blum Robert I President & CEO | $258k | 5,000 | -1% | - | |
| 11Weak | sell 310b5-1 | Malik Fady Ibraham EVP Research & Development | $379k | 7,300 | -6% | - | |
| 13Weak | sell 310b5-1 | WIERENGA WENDALL director | $233k | 4,452 | -15% | - | |
| 4Weak | sell 210b5-1 | Malik Fady Ibraham EVP Research & Development | $396k | 7,300 | -6% | - |
Congressional trades
4 trades in CYTK disclosed by members of Congress under the STOCK Act. All congressional trades.
| Member | Type | Asset | Amount | Traded | Filed |
|---|---|---|---|---|---|
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | CYTK Cytokinetics, Incorporated - Common Stock | $1,001 to $15k | Jun 30, 2026 | 2 days after the trade |
| Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | CYTK Cytokinetics, Incorporated - Common Stock | $1,001 to $15k | Oct 9, 2025 | 40 days after the trade |
| Lisa C. McClain House · R-MI | Sale | CYTK Cytokinetics, Incorporated - Common Stock | $1,001 to $15k | Jun 17, 2025 | 57 days after the trade |
| Lisa C. McClain House · R-MI | Purchase | CYTK Cytokinetics, Incorporated - Common Stock | $1,001 to $15k | Jun 11, 2025 | 63 days after the trade |
Transactions
The last 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 16, 2024 | WIERENGA WENDALL director | MOption exercise Common Stock10b5-1 | +742 | $7.37 | $5,469 | 25,301 | Dec 16, 2024 |
| Dec 16, 2024 | WIERENGA WENDALL director | SOpen-market sale Common Stock10b5-1 | -742 | $48.61 | $36k | 24,559 | Dec 16, 2024 |
| Dec 16, 2024 | WIERENGA WENDALL director | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -742 | $0.00 | $0 | 0 | Dec 16, 2024 |
| Dec 11, 2024 | HENDERSON JOHN T director | MOption exercise Common Stock10b5-1 | +1,780 | $7.37 | $13k | 40,241 | Dec 12, 2024 |
| Dec 11, 2024 | HENDERSON JOHN T director | SOpen-market sale Common Stock10b5-1 | -1,780 | $50.42 | $90k | 38,461 | Dec 12, 2024 |
| Dec 11, 2024 | HENDERSON JOHN T director | MOption exercise Common Stock10b5-1 | +10,092 | $7.37 | $74k | 48,553 | Dec 12, 2024 |
| Dec 11, 2024 | HENDERSON JOHN T director | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -1,780 | $0.00 | $0 | 10,092 | Dec 12, 2024 |
| Dec 11, 2024 | HENDERSON JOHN T director | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -10,092 | $0.00 | $0 | 0 | Dec 12, 2024 |
| Dec 10, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 123,371 | Dec 10, 2024 |
| Dec 10, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -5,300 | $50.63 | $268k | 118,071 | Dec 10, 2024 |
| Dec 10, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -2,000 | $50.65 | $101k | 116,071 | Dec 10, 2024 |
| Dec 10, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 0 | Dec 10, 2024 |
| Dec 3, 2024 | Blum Robert I President & CEO | AGrant or award Common Stock | +11,529 | $0.00 | $0 | 409,207 | Dec 5, 2024 |
| Dec 3, 2024 | Wong Robert VP, Chief Accounting Officer | AGrant or award Common Stock | +764 | $0.00 | $0 | 18,162 | Dec 5, 2024 |
| Dec 3, 2024 | Callos Andrew EVP, Chief Commercial Officer | AGrant or award Common Stock | +3,176 | $0.00 | $0 | 67,063 | Dec 5, 2024 |
| Dec 3, 2024 | Malik Fady Ibraham EVP Research & Development | AGrant or award Common Stock | +4,000 | $0.00 | $0 | 116,099 | Dec 5, 2024 |
| Dec 3, 2024 | Lee Sung EVP, Chief Financial Officer | AGrant or award Common Stock | +4,303 | $0.00 | $0 | 38,987 | Dec 5, 2024 |
| Dec 3, 2024 | Wong Robert VP, Chief Accounting Officer | FTax withholding Common Stock | -273 | $51.51 | $14k | 17,889 | Dec 5, 2024 |
| Dec 3, 2024 | Callos Andrew EVP, Chief Commercial Officer | FTax withholding Common Stock | -1,351 | $51.51 | $70k | 65,712 | Dec 5, 2024 |
| Dec 3, 2024 | Lee Sung EVP, Chief Financial Officer | FTax withholding Common Stock | -1,536 | $51.51 | $79k | 37,451 | Dec 5, 2024 |
| Dec 3, 2024 | Malik Fady Ibraham EVP Research & Development | FTax withholding Common Stock | -2,028 | $51.51 | $104k | 114,071 | Dec 5, 2024 |
| Dec 3, 2024 | Blum Robert I President & CEO | FTax withholding Common Stock | -5,843 | $51.51 | $301k | 403,364 | Dec 5, 2024 |
| Dec 3, 2024 | Malik Fady Ibraham EVP Research & Development | AGrant or award Common Stock | +4,000 | $0.00 | $0 | 118,071 | Dec 5, 2024 |
| Dec 3, 2024 | Callos Andrew EVP, Chief Commercial Officer | AGrant or award Common Stock | +3,177 | $0.00 | $0 | 68,889 | Dec 5, 2024 |
| Dec 3, 2024 | Lee Sung EVP, Chief Financial Officer | AGrant or award Common Stock | +4,304 | $0.00 | $0 | 41,755 | Dec 5, 2024 |
| Dec 3, 2024 | Blum Robert I President & CEO | AGrant or award Common Stock | +11,530 | $0.00 | $0 | 414,894 | Dec 5, 2024 |
| Dec 3, 2024 | Wong Robert VP, Chief Accounting Officer | AGrant or award Common Stock | +766 | $0.00 | $0 | 18,655 | Dec 5, 2024 |
| Dec 2, 2024 | Blum Robert I President & CEO | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,678 | Dec 2, 2024 |
| Dec 2, 2024 | Blum Robert I President & CEO | SOpen-market sale Common Stock10b5-1 | -5,000 | $50.76 | $254k | 397,678 | Dec 2, 2024 |
| Dec 2, 2024 | Blum Robert I President & CEO | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 54,727 | Dec 2, 2024 |
| Nov 25, 2024 | WIERENGA WENDALL director | MOption exercise Common Stock10b5-1 | +742 | $7.37 | $5,469 | 25,301 | Nov 26, 2024 |
| Nov 26, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 119,178 | Nov 26, 2024 |
| Nov 26, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -5,300 | $50.17 | $266k | 113,878 | Nov 26, 2024 |
| Nov 25, 2024 | WIERENGA WENDALL director | SOpen-market sale Common Stock10b5-1 | -742 | $50.00 | $37k | 24,559 | Nov 26, 2024 |
| Nov 26, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -2,000 | $50.14 | $100k | 111,878 | Nov 26, 2024 |
| Nov 25, 2024 | WIERENGA WENDALL director | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -742 | $0.00 | $0 | 742 | Nov 26, 2024 |
| Nov 26, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 5,300 | Nov 26, 2024 |
| Nov 18, 2024 | Blum Robert I President & CEO | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,456 | Nov 19, 2024 |
| Nov 18, 2024 | Blum Robert I President & CEO | SOpen-market sale Common Stock10b5-1 | -5,000 | $50.55 | $253k | 397,456 | Nov 19, 2024 |
| Nov 18, 2024 | Blum Robert I President & CEO | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 59,727 | Nov 19, 2024 |
| Nov 12, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 120,220 | Nov 13, 2024 |
| Nov 12, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -5,300 | $58.48 | $310k | 114,920 | Nov 13, 2024 |
| Nov 12, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -1,042 | $58.48 | $61k | 113,878 | Nov 13, 2024 |
| Nov 12, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 10,600 | Nov 13, 2024 |
| Nov 1, 2024 | Blum Robert I President & CEO | MOption exercise Common Stock10b5-1 | +5,000 | $6.67 | $33k | 402,456 | Nov 4, 2024 |
| Nov 1, 2024 | Blum Robert I President & CEO | SOpen-market sale Common Stock10b5-1 | -5,000 | $51.63 | $258k | 397,456 | Nov 4, 2024 |
| Nov 1, 2024 | Blum Robert I President & CEO | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 64,727 | Nov 4, 2024 |
| Oct 30, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 122,220 | Oct 31, 2024 |
| Oct 28, 2024 | WIERENGA WENDALL director | MOption exercise Common Stock10b5-1 | +4,452 | $7.37 | $33k | 29,011 | Oct 31, 2024 |
| Oct 30, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -5,300 | $51.90 | $275k | 116,920 | Oct 31, 2024 |
| Oct 28, 2024 | WIERENGA WENDALL director | SOpen-market sale Common Stock10b5-1 | -4,452 | $52.25 | $233k | 24,559 | Oct 31, 2024 |
| Oct 30, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -2,000 | $51.93 | $104k | 114,920 | Oct 31, 2024 |
| Oct 28, 2024 | WIERENGA WENDALL director | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -4,452 | $0.00 | $0 | 1,484 | Oct 31, 2024 |
| Oct 30, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 15,900 | Oct 31, 2024 |
| Oct 15, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Common Stock10b5-1 | +5,300 | $7.96 | $42k | 124,220 | Oct 16, 2024 |
| Oct 15, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -5,300 | $54.18 | $287k | 118,920 | Oct 16, 2024 |
| Oct 15, 2024 | Malik Fady Ibraham EVP Research & Development | SOpen-market sale Common Stock10b5-1 | -2,000 | $54.20 | $108k | 116,920 | Oct 16, 2024 |
| Oct 15, 2024 | Malik Fady Ibraham EVP Research & Development | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative10b5-1 | -5,300 | $0.00 | $0 | 21,200 | Oct 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Blum Robert IPresident & CEO
- Callos AndrewEVP, Chief Commercial Officer
- HENDERSON JOHN Tdirector
- Lee SungEVP, Chief Financial Officer
- Malik Fady IbrahamEVP Research & Development
- WIERENGA WENDALLdirector
- Wong RobertVP, Chief Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.